The objective of this study is to determine the efficacy Avenova® (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral Conjunctivitis compared with artificial tears.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
11
Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
Placebo to be used four times a day to the affected eye for 2 weeks
University of Miami Bascom Palmer Eye Institute
Miami, Florida, United States
Number of Participants With Clinical Resolution of Viral Conjunctivitis
This is the number of participants who on day 7 (+/-1 days) had on clinical examination a 0 or 1 on the follicular conjunctivitis scale and 0 or 1 on the conjunctival injection scale.
Time frame: Up to 8 days
Number of Participants With Symptomatic Resolution of Viral Conjunctivitis
This is the number of participants who on day 7 (+/-1 days) answered on clinical questionaire "none" or "mild" to each of the following list of 7 symptoms: "overall symptoms that affect your daily activities", "itching", "tearing", "pain", "feeling that your lids are stuck together in the morning", "sensitivity to light", "blurry vision"
Time frame: Up to 8 days
Number of Participants With Undetectable Adenoviral DNA
This is the number of participants who on day 7 (+/-1 days) had undetectable adenoviral DNA by quantitative Polymerase Chain Reaction (qPCR) (Ct \> 35)
Time frame: Up to 8 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.